NEXTURNBIOSCIENCE Co., Ltd.

Equities

A089140

KR7089140008

Industrial Machinery & Equipment

End-of-day quote Korea S.E. 03:30:00 07/06/2024 am IST 5-day change 1st Jan Change
3,615 KRW +0.70% Intraday chart for NEXTURNBIOSCIENCE Co., Ltd. -0.69% -34.51%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NEXTURNBIOSCIENCE Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NEXTURNBIOSCIENCE Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Mirae Corporation announced that it has received KRW 2.6 billion in funding from NEXTURNBIOSCIENCE Co., Ltd., UA Co.,Ltd CI
Mirae Corporation announced that it has received KRW 10 billion in funding from NEXTURNBIOSCIENCE Co., Ltd. CI
NEXTURNBIOSCIENCE Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 7 billion in funding from Flask Co., Ltd., GLK Equity Investment Co., Ltd., SAMSUNG PHARM. Co., LTD., CMG Pharmaceutical Co., Ltd. CI
NexturnBioScience Plans 1 Billion Won Capital Raise through Stock Offering; Shares Jump 4% MT
NEXTURNBIOSCIENCE Co., Ltd. announced that it has received KRW 5.9999959 billion in funding CI
NEXTURNBIOSCIENCE Co., Ltd. completed the acquisition of 10.59% stake in Mirae Corporation from KANGLIM Co., Ltd. CI
Mirae Corporation announced that it expects to receive KRW 5 billion in funding from NEXTURNBIOSCIENCE Co., Ltd., UA Co.,Ltd CI
Mirae Corporation announced that it expects to receive KRW 15 billion in funding from NEXTURNBIOSCIENCE Co., Ltd. CI
Mirae Corporation announced that it expects to receive KRW 15 billion in funding from NEXTURNBIOSCIENCE Co., Ltd. CI
NEXTURNBIOSCIENCE Co., Ltd. agreed to acquire a 10.59% stake in Mirae Corporation from KANGLIM Co., Ltd. CI
NEXTURNBIOSCIENCE Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
NEXTURNBIOSCIENCE Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
NEXTURNBIOSCIENCE Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
NEXTURNBIOSCIENCE Co., Ltd. cancelled the transaction announced on March 31, 2022 CI
NEXTURNBIOSCIENCE Co., Ltd.(KOSDAQ:A089140) dropped from S&P Global BMI Index CI
NEXTURNBIOSCIENCE Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
NEXTURNBIOSCIENCE Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
NEXTURNBIOSCIENCE Co., Ltd. agreed to acquire a 78.9% stake in Roll Korea Co., Ltd. from Ma Su Ran and Kim Jong Kyu for KRW 13.4 billion. CI
NexturnBioScience to Raise Funds via Share Issuance MT
NexturnBioscience Co., Ltd announced that it expects to receive KRW 13.99999433 billion in funding CI
NEXTURNBIOSCIENCE Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
NexturnBioscience Co., Ltd announced that it has received KRW 10 billion in funding from SL Vionics Co., Ltd. CI
Chart NEXTURNBIOSCIENCE Co., Ltd.
More charts
NexturnBioScience Co Ltd, formerly Nexturn Co Ltd, is a Korea-based company principally engaged in the manufacture and sale of computer numerical control (CNC) automatic lathes. The Company's products are used for automobile parts such as engine parts, steering devices, wipers and others, marine engine parts, medical devices and implants, communication equipment such as mobile phones, digital multimedia broadcasting (DMB) devices and others, electronic components such as liquid crystal display (LCD), copier, printer and others, hydraulic and pneumatic parts, among others. It also provides related parts, after-sales service.
More about the company
  1. Stock Market
  2. Equities
  3. A089140 Stock
  4. News NEXTURNBIOSCIENCE Co., Ltd.
  5. NexturnBioScience to Raise Funds via Share Issuance